CNS Drugs

, Volume 19, Issue 5, pp 445–464 | Cite as

Acamprosate

A Review of its Use in the Maintenance of Abstinence in Patients with Alcohol Dependence
  • Lesley J. Scott
  • David P. Figgitt
  • Susan J. Keam
  • John Waugh
Adis Drug Evaluation

Summary

Abstract

Acamprosate (Campral® delayed-release tablet), a synthetic compound with a similar structure to that of the neurotransmitter GABA and the neuromodulator taurine, facilitates the maintenance of abstinence in detoxified alcohol-dependent patients. Although the precise mechanism(s) of action of the drug remains to be fully elucidated, it appears that it most likely involves beneficial modulation of the glutamatergic neurotransmitter system, including antagonism of the mGLu5 metabotropic glutamate receptor, to counteract the imbalance between the glutamatergic and GABAergic systems associated with chronic alcohol exposure and alcohol withdrawal.

In several double-blind, placebo-controlled trials of up to 12 months’ duration, acamprosate effectively maintained complete abstinence in detoxified alcohol-dependent patients, irrespective of disease severity or the type of psychosocial support. The drug showed better efficacy than placebo and was very well tolerated. Limited data from a relatively well designed trial indicate that the drug has similar efficacy to that of naltrexone and that combination therapy with these two agents provides better efficacy than acamprosate monotherapy, although multicentre direct head-to-head investigations are required to fully establish the potential of this combination. The drug may be particularly useful in those with hepatic impairment and/or liver disease. Thus, in combination with psychosocial and behavioural management programmes, acamprosate is a promising option for the maintenance of abstinence in alcohol-dependent patients after alcohol withdrawal.

Pharmacological Properties

Chronic alcohol exposure is thought to negatively alter the balance between the excitation of glutamatergic neurotransmitter systems and the inhibition of GABAergic neurotransmitter systems; the imbalance between these two systems is most likely associated with the development of tolerance to the effects of alcohol and alcohol-withdrawal symptomatology. Although acamprosate has a similar structure to that of GABA, in vitro and in vivo evidence suggests that key mechanism of action results from modification of the glutamatergic neurotransmitter system, particularly via modulation of activity at the NMDA receptor that is possibly mediated through modulation of the polyamine receptor site and/or via antagonism at the metabotropic mGlu5 receptor. In various animal models, acamprosate dose-dependently reduces acute and chronic alcohol self-administration and blocks the alcohol withdrawal-induced increase in glutamate. In in vitro studies, it reduced glutamate-induced neurotoxicity associated with alcohol withdrawal in cortical and hippocampal cell cultures and attenuated (±)-l-amino-cyclopentane-trans-l, 3-dicarboxylic acid (trans-ACPD)-induced neurotoxicity as seen in hippocampal slices from rats that had been chronically exposed to ethanol.

Peak plasma concentrations were achieved 5.5–7.3 hours after administration of oral acamprosate 1998 mg/day, with steady-state plasma concentrations achieved within 5 days. Bioavailability is low (absolute bioavailability ≈11%) and protein binding is negligible. The drug is widely distributed throughout the body (volume of distribution after intravenous administration is ≈1 L/kg [72–109L]); animal studies have shown that the drug can cross the blood-brain barrier. Acamprosate is not metabolised and is primarily excreted via the kidneys as unchanged drug, with a mean terminal elimination half-life of 18–33 hours. The pharmacokinetics of acamprosate are not affected by hepatic impairment. Total body and renal clearances of the drug are significantly reduced in renal impairment; dosage adjustments are required in patients with moderate renal impairment and the drug is contraindicated in those with severe renal impairment. No clinically relevant interactions are seen when the drug is coadministered with alcohol or medications used to treat alcohol dependence or common co-morbidities in this patient population, such as disulfiram, naltrexone, diazepam or imipramine.

Therapeutic Efficacy

Acamprosate, in combination with psychosocial therapy, was generally significantly more effective than placebo at maintaining complete abstinence in well designed trials of 3–12 months’ duration enrolling ≈3500 alcohol-dependent patients aged 18–65 years. In double-blind trials, treatment for 6 months’ with oral acamprosate 1332–1998 mg/day (dosage based on bodyweight) was generally associated with significantly more patients remaining completely abstinent (12–48% vs 11–33%), a longer mean cumulative abstinence duration (CAD; 61–110 vs 43–89 days), and a longer median time to first drink (TFD; 45–151 vs 15–61 days) than placebo. Where reported, after 6 months’ post-treatment follow-up, the beneficial effect of acamprosate on mean CAD was maintained. In addition, in a 3-month trial, acamprosate 1332 mg/day treatment was as effective as acamprosate 1998 mg/day in maintaining complete abstinence, with both dosages being more effective than placebo (acamprosate dosage given irrespective of bodyweight). Longer term placebo-controlled trials (11–12 months’ treatment) generally confirmed the superiority of acamprosate 1332–1998 mg/day over placebo in terms of abstinence endpoints. Significantly more acamprosate than placebo recipients remained completely abstinent (18–45% vs 7–25%) and the mean CAD was significantly longer in the acamprosate arms (175–225 vs 104–162 days). In general, the mean CAD remained significantly longer in acamprosate recipients during the 6- to 12-month post-treatment follow-up period.

Furthermore, coadministration of acamprosate and naltrexone was more effective in maintaining complete abstinence than acamprosate alone. In this 3-month, single-centre trial (n = 40 patients/group), the probability towards the first drink was significantly lower with acamprosate 1998 mg/day, naltrexone 50 mg/day or acamprosate plus naltrexone than with placebo in alcohol-dependent patients, with acamprosate plus naltrexone being more effective than acamprosate alone at preventing relapse to heavy drinking. In terms of maintaining complete abstinence (i.e. mean TFD; secondary endpoint), there was no intergroup difference between acamprosate 1665–1998 mg/day and naltrexone 50 mg/day in a 1-year single-blind study in alcohol-dependent patients; nevertheless, acamprosate was not as effective as naltrexone in terms of mean CAD or mean time to heavy drinking (primary endpoints).

Tolerability

Acamprosate is very well tolerated in abstinent alcohol-dependent patients. The incidence of adverse events with acamprosate was similar to that with placebo in clinical trials, with the exception of diarrhoea, which was the most frequently reported adverse event in either treatment group (16% vs 10%; no statistical analysis reported). Results from pooled pre- and postmarketing analyses in >7000 patients who received the drug for up to 1 year confirmed the good tolerability of acamprosate.

Keywords

Alcohol Dependence Naltrexone Alcohol Withdrawal Disulfiram Acamprosate 

References

  1. 1.
    Pelc I, Ansoms C, Lehert P, et al. The European NEAT program: an integrated approach using acamprosate and psychosocial support for the prevention of relapse in alcohol-dependent patients with a statistical modeling of therapy success prediction. Alcohol Clin Exp Res 2002; 26(10): 1529–38PubMedCrossRefGoogle Scholar
  2. 2.
    Swift RM. Drug therapy for alcohol dependence. N Engl J Med 1999; 340(19): 1482–90PubMedCrossRefGoogle Scholar
  3. 3.
    Dongier M. Brain, alcohol and alcoholism treatment. Ann R Coll Physicians Surg Can 1993; 26(1): 26–8Google Scholar
  4. 4.
    Garbutt JC, West SL, Carey TS, et al. Pharmacological treatment of alcohol dependence: a review of the evidence. JAMA 1999; 281(14): 1318–25PubMedCrossRefGoogle Scholar
  5. 5.
    Saitz R. Unhealthy alcohol use. N Engl J Med 2005; 352(6): 596–607PubMedCrossRefGoogle Scholar
  6. 6.
    Wilde MI, Goa KL. Management of alcohol dependence after detoxification: the potential role of acamprosate. Dis Manage Health Outcomes 1998 Jan; 3(1): 35–46CrossRefGoogle Scholar
  7. 7.
    De Witte P, Littleton J, Parot P, et al. Neuroprotective and abstinence-promoting effects of acamprosate: elucidating the mechanism of action. CNS Drugs (in press)Google Scholar
  8. 8.
    Mann K. Pharmacotherapy of alcohol dependence: a review of the clinical data. CNS Drugs 2004; 18(8): 485–504PubMedCrossRefGoogle Scholar
  9. 9.
    De Witte P. Imbalance between neuroexcitatory and neuroinhibitory amino acids causes craving for ethanol. Addict Behav 2004 Sep; 29(7): 1325–39PubMedCrossRefGoogle Scholar
  10. 10.
    Forest Pharmaceuticals Inc. CAMPRAL® (acamprosate calcium) delayed-release tablets prescribing information [online]. Available from URL: http://www.campral.com [Accessed 2005 Apr 11]
  11. 11.
    Wilde MI, Wagstaff AJ. Acamprosate: a review of its pharmacology and clinical potential in the management of alcohol dependence after detoxification. Drugs 1997; 53(6): 1038–53PubMedCrossRefGoogle Scholar
  12. 12.
    Littleton J, Zieglgänsberger W. Pharmacological mechanisms of naltrexone and acamprosate in the prevention of relapse in alcohol dependence. Am J Addict 2003; 12 Suppl 1: 3S–11SCrossRefGoogle Scholar
  13. 13.
    Harris BR, Gibson A, Prendergast MA, et al. The neurotoxicity induced by ethanol withdrawal in mature organotypic hippo-campal slices might involve cross-talk between metabotropic glutamate type 5 receptors and N-methyl-D-aspartate receptors. Alcohol Clin Exp Res 2003; 27(11): 1724–35PubMedCrossRefGoogle Scholar
  14. 14.
    Harris BR, Prendergast MA, Gibson DA, et al. Acamprosate inhibits the binding and neurotoxic effects of trans-ACPD, suggesting a novel site of action at metabotropic glutamate receptors. Alcohol Clin Exp Res 2002; 26(12): 1779–93PubMedCrossRefGoogle Scholar
  15. 15.
    Zornoza T, Cano MJ, Polache A, et al. Pharmacology of acamprosate: an overview. CNS Drug Rev 2003; 9(4): 359–74PubMedCrossRefGoogle Scholar
  16. 16.
    Spanagel R, Putzke J, Schobitz B, et al. Acamprosate and alcohol: II. Effects on alcohol withdrawal in the rat. Eur J Pharmacol 1996; 305: 45–50Google Scholar
  17. 17.
    Spanagel R, Hölter SM, Allingham K, et al. Acamprosate and alcohol: I. Effects on alcohol intake following alcohol deprivation in the rat. Eur J Pharmacol 1996; 305(1-3): 39–44PubMedCrossRefGoogle Scholar
  18. 18.
    Heyser CJ, Schulteis G, Durbin P, et al. Chronic acamprosate eliminates the alcohol deprivation effect while having limited effects on baseline responding for ethanol in rats. Neurop-sychopharmacology 1998; 18(2): 125–33CrossRefGoogle Scholar
  19. 19.
    Le Magnen J, Tran G, Durlach J, et al. Dose-dependent suppression of the high alcohol intake of chronically intoxicated rats by Ca-acetyl homotaurinate. Alcohol 1987; 4(2): 97–102PubMedCrossRefGoogle Scholar
  20. 20.
    Czachowski CL, Legg BH, Samson HH. Effects of acamprosate on ethanol-seeking and self-administration in the rat. Alcohol Clin Exp Res 2001; 25(3): 344–50PubMedCrossRefGoogle Scholar
  21. 21.
    Dahchour A, De Witte P. Effects of acamprosate on excitatory amino acids during multiple ethanol withdrawal periods. Alcohol Clin Exp Res 2003; 27(3): 465–70PubMedCrossRefGoogle Scholar
  22. 22.
    Putzke J, Spanagel R, Tölle TR, et al. The anti-craving drug acamprosate reduces c-fos expression in rats undergoing ethanol withdrawal. Eur J Pharmacol 1996; 317: 39–48PubMedCrossRefGoogle Scholar
  23. 23.
    al Qatari M, Khan S, Harris B, et al. Acamprosate is neuroprotective against glutamate-induced excitotoxicity when enhanced by ethanol withdrawal in neocortical cultures of fetal rat brain. Alcohol Clin Exp Res 2001; 25(9): 1276–83PubMedCrossRefGoogle Scholar
  24. 24.
    Mayer S, Harris BR, Gibson DA, et al. Acamprosate, MK801, and ifenprodil inhibit neurotoxicity and calcium entry induced by ethanol withdrawal in organotypic slice cultures from neonatal rat hippocampus. Alcohol Clin Exp Res 2002; 26(10): 1468–78PubMedCrossRefGoogle Scholar
  25. 25.
    Saivin S, Hulot T, Chabac S, et al. Clinical pharmacokinetics of acamprosate. Clin Pharmacokinet 1998; 35(5): 331–45PubMedCrossRefGoogle Scholar
  26. 26.
    Durbin P, Hulot T, Chabac S. Pharmacodynamics and pharmacokinetics of acamprosate: an overview. In: Soyka M, editor. Acamprosate in relapse prevention of alcoholism. Proceedings of the 1st Campral-symposium ESBRA Stuttgart. Germany, Springer 1995, 47–64Google Scholar
  27. 27.
    Geerlings PJ, Ansoms C, van den Brink W. Acamprosate and prevention of relapse in alcoholics. Eur Addict Res 1997; 3: 129–37CrossRefGoogle Scholar
  28. 28.
    Gual A, Lehert P. Acamprosate during and after acute alcohol withdrawal: a double-blind placebo-controlled study in Spain. Alcohol Alcohol 2001; 36(5): 413–8PubMedGoogle Scholar
  29. 29.
    Chick J, Howlett H, Morgan MY, et al. United Kingdom Multicentre Acamprosate Study (UKMAS): a 6-month prospective study of acamprosate versus placebo in preventing relapse after withdrawal from alcohol. Alcohol Alcohol 2000; 35(2): 176–87PubMedGoogle Scholar
  30. 30.
    Poldrugo F. Acamprosate treatment in a long-term community-based alcohol rehabilitation programme. Addiction 1997; 92(11): 1537–46PubMedCrossRefGoogle Scholar
  31. 31.
    Pelc I, Verbanck P, Le Bon O, et al. Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients: a 90-day placebo-controlled dose-finding study. Br J Psychiatry 1997; 171: 73–7PubMedCrossRefGoogle Scholar
  32. 32.
    Tempesta E, Janiri L, Bignamini A, et al. Acamprosate and relapse prevention in the treatment of alcohol dependence: a placebo-controlled study. Alcohol Alcohol 2000; 35(2): 202–9PubMedGoogle Scholar
  33. 33.
    Whitworth AB, Fischer F, Lesch OM, et al. Comparison of acamprosate and placebo in long-term treatment of alcohol dependence. Lancet 1996; 347: 1438–42PubMedCrossRefGoogle Scholar
  34. 34.
    Paille FM, Guelfi JD, Perkins AC, et al. Double-blind randomized multicentre trial of acamprosate in maintaining abstinence from alcohol. Alcohol Alcohol 1995; 30(2): 239–47PubMedGoogle Scholar
  35. 35.
    Sass H, Soyka M, Mann K, et al. Relapse prevention by acamprosate: results from a placebo-controlled study on alcohol dependence. Arch Gen Psychiatry 1996; 53: 673–80PubMedCrossRefGoogle Scholar
  36. 36.
    Barrias JA, Chabac S, Fereirra L, et al. Acamprosate: multicenter Portuguese efficacy and tolerance evaluation study [in Portuguese]. Psiquiatria Clinica 1997; 18(2): 149–60Google Scholar
  37. 37.
    Lhuintre JP, Moore N, Tran G, et al. Acamprosate appears to decrease alcohol intake in weaned alcoholics. Alcohol Alcohol 1990; 25(6): 613–22PubMedGoogle Scholar
  38. 38.
    Morgan MY, Landron F, Lehert P, for the New European Alcoholism Treatment Study Group. Improvement in quality of life after treatment for alcohol dependence with acamprosate and psychosocial support. Alcohol Clin Exp Res 2004; 28(1): 64–77PubMedCrossRefGoogle Scholar
  39. 39.
    Kiritzé-Topor P, Huas D, Rosenzweig C, et al. A pragmatic trial of acamprosate in the treatment of alcohol dependence in primary care. Alcohol Alcohol 2004; 39(6): 520–7PubMedGoogle Scholar
  40. 40.
    Ansoms C, Deckers F, Lehert P, et al. An open study with acamprosate in Belgium and Luxemburg: results on sociode-mographics, supportive treatment and outcome. Eur Addict Res 2000 Sep; 6(3): 132–40PubMedCrossRefGoogle Scholar
  41. 41.
    Kiefer F, Jahn H, Tarnaske T, et al. Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism. Arch Gen Psychiatry 2003; 60: 92–9PubMedCrossRefGoogle Scholar
  42. 42.
    Rubio G, Jiménez-Arriero MA, Ponce G, et al. Naltrexone versus acamprosate: one year follow-up of alcohol dependence treatment. Alcohol Alcohol 2001; 36(5): 419–25PubMedGoogle Scholar
  43. 43.
    US FDA Center for Drug Evaluation and Research. NDA 21–431: acamprosate calcium tablets [online]. Available from URL: http://www.fda.gov [Accessed 2005 May 3]
  44. 44.
    De Wildt WA, Schippers GM, Van Den Brink W, et al. Does psychosocial treatment enhance the efficacy of acamprosate in patients with alcohol problems? Alcohol Alcohol 2002; 37(4): 375–82PubMedGoogle Scholar
  45. 45.
    Verheul R, Lehert P, Geerlings PJ, et al. Predictors of acamprosate efficacy: results from a pooled analysis of seven European trials including 1485 alcohol-dependent patients. Psychophar-macology (Berl) 2005; 178: 167–73CrossRefGoogle Scholar
  46. 46.
    Merck Pharmaceuticals. Campral® EC: summary of product characteristics [online]. Available from URL: http://emc.medicines.org.uk [Accessed 2005 Apr 26]
  47. 47.
    Anton RF, Swift RM. Current pharmacotherapies of alcoholism: a US perspective. Am J Addict 2003; 12Suppl. 1: S53–68PubMedCrossRefGoogle Scholar
  48. 48.
    Scottish Intercollegiate Guidelines Network. The management of harmful drinking and alcohol dependence in primary care: a national clinical guideline [online]. Available from URL: http://www.sign.ac.uk [Accessed 2005 Apr 12]
  49. 49.
    Annemans L, Vanoverbeke N, Tecco J, et al. Economic evaluation of Campral® (acamprosate) compared to placebo in maintaining abstinence in alcohol-dependent patients. Eur Addict Res 2000; 6(2): 71–8PubMedCrossRefGoogle Scholar
  50. 50.
    Management of Substance Use Disorders Working Group. VHA/DoD clinical practice guideline for the management of substance use disorders, Washington (DC): Veterans Health Administration, Department of Defence [online]. Available from URL: http://www.guideline.gov [Accessed 2005 Apr 12]
  51. 51.
    Fuller RK, Branchy L, Brightwell DL, et al. Disulfiram treatment of alcoholism: a Veterans Administration cooperative study. JAMA 1986; 256(11): 1449–55PubMedCrossRefGoogle Scholar
  52. 52.
    UK Alcohol Forum. UK alcohol forum guidelines [online]. Available from URL: http://www.ukalcoholforum.org [Accessed 2005 Apr 26]
  53. 53.
    American Society of Health-System Pharmacists. Naltrexone hydrochloride. In: McEnvoy GK, editor. American Hospital Formulary Services Drug Information. Bethesda (MD): Datapharma Publications Limited, 2005: 2108–15Google Scholar
  54. 54.
    American Society of Health-System Pharmacists. Disulfiram. In: McEnvoy GK, editor. American Hospital Formulary Services Drug Information. Bethesda (MD): Datapharma Publications Limited, 2005: 3558–9Google Scholar
  55. 55.
    Mason BJ. Acamprosate. Recent Dev Alcohol 2003; 16: 203–15PubMedCrossRefGoogle Scholar
  56. 56.
    Overman GP, Teter CJ, Guthrie SK. Acamprosate for the adjunctive treatment of alcohol dependence. Ann Pharmacother 2003; 37: 1090–9PubMedCrossRefGoogle Scholar
  57. 57.
    Bouza C, Magro A, Muñoz A, et al. Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review. Addiction 2004; 99(7): 811–28PubMedCrossRefGoogle Scholar
  58. 58.
    Mann K, Lehert P, Morgan MY. The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: results of a meta-analysis. Alcohol Clin Exp Res 2004; 28(1): 51–63PubMedCrossRefGoogle Scholar
  59. 59.
    Mason BJ, Ownby RL. Acamprosate for the treatment of alcohol dependence: a review of double-blind, placebo-controlled trials. CNS Spectr 2000; 5(2): 58–69PubMedGoogle Scholar
  60. 60.
    Soyka M, Chick J. Use of acamprosate and opioid antagonists in the treatment of alcohol dependence: a European perspective. Am J Addict 2003; 12 Suppl 1: 69S–80SCrossRefGoogle Scholar
  61. 61.
    Chick J, Lehert P, Landron F, for the Plinius Maior Society. Does acamprosate improve reduction of drinking as well as aiding abstinence? J Psychopharmacol 2003; 17(4): 397–402PubMedCrossRefGoogle Scholar
  62. 62.
    Kiefer F, Wiedemann K. Combined therapy: what does acamprosate and naltrexone combination tell us? Alcohol Alcohol 2004; 39(6): 542–7PubMedGoogle Scholar
  63. 63.
    COMBINE Study Research Group. Testing combined pharmacotherapies and behavioural interventions for alcohol ependence (The COMBINE Study): a pilot feasability study. Alcohol Clin Exp Res 2003; 27(7): 1123–31CrossRefGoogle Scholar
  64. 64.
    Besson J, Aeby F, Kasas A, et al. Combined efficacy of acamprosate and disulfiram in the treatment of alcoholism: a controlled study. Alcohol Clin Exp Res 1998; 22(3): 573–9PubMedCrossRefGoogle Scholar
  65. 65.
    Foster RH, McClellan KJ. Acamprosate: pharmacoeconomic implications of therapy. Pharmacoeconomics 1999; 16(6): 743–55PubMedCrossRefGoogle Scholar
  66. 66.
    Rychlik R, Siedentop H, Pfeil T, et al. Cost-effectiveness of adjuvant treatment with acamprosate in maintaining abstinence in alcohol dependent patients. Eur Addict Res 2003; 9(2): 59–64PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2005

Authors and Affiliations

  • Lesley J. Scott
    • 1
  • David P. Figgitt
    • 1
  • Susan J. Keam
    • 1
  • John Waugh
    • 1
  1. 1.Adis International LimitedMairangi Bay, AucklandNew Zealand

Personalised recommendations